Body’s Own Healing Mechanisms Could Reverse Lung Fibrosis
Researchers have identified a molecular pathway that leverages the body's natural healing processes to potentially reverse idiopathic pulmonary fibrosis.
Tag: pulmonary fibrosis and IPF
All
Latest
All
Latest
Aileron Acquires Lung Therapeutics to Advance IPF Drug Candidate
Aileron Therapeutics acquired Lung Therapeutics Inc, a biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications.
All
Latest
Novel Imaging Agent Enables Early Detection of Pulmonary Fibrosis
A newly developed PET imaging agent can non-invasively identify pulmonary fibrosis in its early stages, reducing the need for unnecessary biopsies and allowing patients to begin treatment sooner.
Pilot Study Explores Early Detection of IPF Using X-Ray and AI
The study is investigating the possibility that X-ray imaging, when used with artificial intelligence, could facilitate earlier diagnosis and eventually more effective management of idiopathic pulmonary fibrosis.
Read More
aTyr Announces Phase 2 Study of SSc-ILD Drug
The expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
Read More
Toolkit to Support Clinicians in Quicker Diagnosis of ILDs
The new toolkit, shared on Rare Disease Day, aims to help clinicians shorten the time to diagnosis for pulmonary fibrosis and other interstitial lung diseases.
Read More
Patient & Caregiver Network Offers Aid to COPD, Asthma Patients
The American Lung Association has launched its Patient & Caregiver Network to support over 34 million Americans diagnosed with COPD, asthma, and other lung diseases.
Read More
Interstitial Lung Disease in Hospitalized COVID Patients
Approximately 11% of hospitalized COVID-19 patients had fibrotic patterning after recovery from acute illness, according to a new study from Imperial College London researchers published in AJRCCM.
Read More
Interstitial Lung Disease Common After COVID-19
Researchers estimated that up to 11% of hospitalized COVID-19 patients had interstitial lung disease after recovery from COVID.
Read More
Airway Protein May Be Key to Body’s Mucociliary Clearance
MUC5AC, an airway protein, plays an important (and overlooked) role in the body’s mucociliary clearance system, according to research published in Science Advances.
Read MoreCOPD: Trial of Home-Based Rehab Shows Promising Results
A multicenter randomized controlled trial of a home-based rehabilitation program for patients with chronic obstructive pulmonary disease (COPD) showed highly positive results.
Read More
Zinc May Reverse Pulmonary Fibrosis
Zinc, a common mineral, may reverse lung damage and improve survival for patients with idiopathic pulmonary fibrosis (IPF), according to researchers from the Women’s Guild Lung Institute at Cedars-Sinai.
Read More
Pulmonary Fibrosis Research on Access, Quality of Care
Important research results from five studies examining access to care and outcomes for patients living with pulmonary fibrosis and interstitial lung disease (ILD) are being presented at ATS 2022.
Read More
Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines Issued
Updated clinical practice guidelines from ATS/ERS cover idiopathic pulmonary fibrosis and address progressive pulmonary fibrosis in patients with interstitial lung diseases other than IPF.
Read More
Study: Nintedanib for Idiopathic Pulmonary Fibrosis
A study in the journal Respiration showed that patients with idiopathic pulmonary fibrosis who were treated with nintedanib saw more positive outcomes.
Read More